These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

113 related articles for article (PubMed ID: 16900456)

  • 1. Model selection and mixed-effects modeling of HIV infection dynamics.
    Bortz DM; Nelson PW
    Bull Math Biol; 2006 Nov; 68(8):2005-25. PubMed ID: 16900456
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Skew-normal Bayesian nonlinear mixed-effects models with application to AIDS studies.
    Huang Y; Dagne G
    Stat Med; 2010 Oct; 29(23):2384-98. PubMed ID: 20603815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The V118I mutation as a marker of advanced HIV infection and disease progression.
    Zaccarelli M; Tozzi V; Lorenzini P; Forbici F; Narciso P; Ceccherini-Silberstein F; Trotta MP; Bertoli A; Liuzzi G; Marconi P; Mosti S; Perno CF; Antinori A
    Antivir Ther; 2007; 12(2):163-8. PubMed ID: 17503658
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Bayesian approach to parameter estimation in HIV dynamical models.
    Putter H; Heisterkamp SH; Lange JM; de Wolf F
    Stat Med; 2002 Aug; 21(15):2199-214. PubMed ID: 12210633
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nature of equilibria and effects of drug treatments in some simple viral population dynamical models.
    Tuckwell HC; Wan FY
    IMA J Math Appl Med Biol; 2000 Dec; 17(4):311-27. PubMed ID: 11270747
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Sensitivity analysis of a nonlinear lumped parameter model of HIV infection dynamics.
    Bortz DM; Nelson PW
    Bull Math Biol; 2004 Sep; 66(5):1009-26. PubMed ID: 15294416
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A viral load-based cellular automata approach to modeling HIV dynamics and drug treatment.
    Shi V; Tridane A; Kuang Y
    J Theor Biol; 2008 Jul; 253(1):24-35. PubMed ID: 18083195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Estimation and prediction with HIV-treatment interruption data.
    Adams BM; Banks HT; Davidian M; Rosenberg ES
    Bull Math Biol; 2007 Feb; 69(2):563-84. PubMed ID: 17211735
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I and II study of the safety, virologic effect, and pharmacokinetics/pharmacodynamics of single-dose 3-o-(3',3'-dimethylsuccinyl)betulinic acid (bevirimat) against human immunodeficiency virus infection.
    Smith PF; Ogundele A; Forrest A; Wilton J; Salzwedel K; Doto J; Allaway GP; Martin DE
    Antimicrob Agents Chemother; 2007 Oct; 51(10):3574-81. PubMed ID: 17638699
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fuzzy modeling in symptomatic HIV virus infected population.
    Jafelice RM; de Barros LC; Bassanezi RC; Gomide F
    Bull Math Biol; 2004 Nov; 66(6):1597-620. PubMed ID: 15522347
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immunological responses during a virologically failing antiretroviral regimen are associated with in vivo synonymous mutation rates of HIV type-1 env.
    Mens H; Jørgensen LB; Kronborg G; Schønning K; Benfield T
    Antivir Ther; 2009; 14(3):413-22. PubMed ID: 19474475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. HIV-1 genotype after interruption of non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy and virological response after resumption of the same regimen.
    Sungkanuparph S; Kiertiburanakul S; Apisarnthanarak A; Malathum K; Sathapatayavongs B
    Int J STD AIDS; 2007 Dec; 18(12):832-4. PubMed ID: 18073016
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Practical identifiability of HIV dynamics models.
    Guedj J; Thiébaut R; Commenges D
    Bull Math Biol; 2007 Nov; 69(8):2493-513. PubMed ID: 17557186
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV-1 drug resistance mutations in children who failed non-nucleoside reverse transcriptase inhibitor-based antiretroviral therapy.
    Sungkanuparph S; Apiwattanakul N; Thitithanyanont A; Chantratita W; Sirinavin S
    Southeast Asian J Trop Med Public Health; 2009 Jan; 40(1):83-8. PubMed ID: 19323038
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Uncertainty quantification in modeling HIV viral mechanics.
    Banks HT; Baraldi R; Cross K; Flores K; McChesney C; Poag L; Thorpe E
    Math Biosci Eng; 2015 Oct; 12(5):937-64. PubMed ID: 26280189
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetic variability of antiretroviral drugs and correlation with virological outcome: 2 years of experience in routine clinical practice.
    Fabbiani M; Di Giambenedetto S; Bracciale L; Bacarelli A; Ragazzoni E; Cauda R; Navarra P; De Luca A
    J Antimicrob Chemother; 2009 Jul; 64(1):109-17. PubMed ID: 19398461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Score tests for exploring complex models: application to HIV dynamics models.
    Drylewicz J; Commenges D; Thiébaut R
    Biom J; 2010 Feb; 52(1):10-21. PubMed ID: 19937998
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of HIV-1 kinetic models using quantitative discrimination analysis.
    Knorr AL; Srivastava R
    Bioinformatics; 2005 Apr; 21(8):1668-77. PubMed ID: 15613395
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Modeling the short-, middle- and long-term viral load responses for comparing estimated dynamic parameters.
    Huang Y
    Biom J; 2007 Jun; 49(3):429-40. PubMed ID: 17623347
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prevalence of CXCR4 tropism among antiretroviral-treated HIV-1-infected patients with detectable viremia.
    Hunt PW; Harrigan PR; Huang W; Bates M; Williamson DW; McCune JM; Price RW; Spudich SS; Lampiris H; Hoh R; Leigler T; Martin JN; Deeks SG
    J Infect Dis; 2006 Oct; 194(7):926-30. PubMed ID: 16960780
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.